Bio-heart Launches Iberis Renal Ablation System at OCC 2025
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...
BioAge Labs Partners with JiKang for APJ Agonist Nanobody License
US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...
Bayer’s Nubeqa Gets FDA Approval for mHSPC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration...
Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer
Sainte Nutritional Inc., China’s leading provider of Food for Special Medical Purpose (FSMP), has filed...
Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study...
Harbin Gloria Partners with Eisai to Promote Methycobal in China
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has entered into a market promotion service...
Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler
Beijing-based Lepu Medical Technology (SHE: 300003), a provider of cardiovascular disease solutions, announced that its...
JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...
Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...
EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years
China Central Television (CCTV) reported that EU member states have voted under the International Procurement...
Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025
China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...
EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen
Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...
Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced the enrollment of the first patient...
Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline
French pharmaceutical giant Sanofi (NASDAQ: SNY) announced plans to acquire US-based Blueprint Medicines Corporation for...
BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors
Germany-based BioNTech SE (NASDAQ: BNTX) announced a strategic partnership with US major Bristol-Myers Squibb (BMS,...
Harbin Pharma Agrees to Acquire Clinical Approval for Jesduvroq from Bocimed
China’s Harbin Pharmaceutical Group Holding Co., Ltd (SHA: 600664) announced a technology transfer agreement with...
Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Huadong Medicine Files for NMPA Approval of Ranibizumab Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market approval filing for a...